ClinicalTrials.gg
RecruitingNCT05056467FORECAST-IOLUpdated May 19, 2023

Labor Induction in Preeclampsia High-risk Women

An interventional study of Induction of Labor in Pre-Eclampsia and Induction of Labor, sponsored by Chinese University of Hong Kong. Recruiting at 8 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-19.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
825
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Pre-Eclampsia with a site in China — 12 open to participants now, 13 under way, 2 of them phase 3. Pre-Eclampsia · China.

Planned enrollment
7th of 19
825 · median 180
Started
2022
with 3 others
No phase
12 of 36
5 open now
Primary completion
2024-08
later than 0 of 12 live
Registered
18th of 36
by date
Lead sponsor
2 of 36
Chinese University of Hong Kong

Among the 36 studies in Pre-Eclampsia with a site in China, this one is the 7th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2022, is one of 12 with no phase, reaches primary completion later than 0 of the 12 other live ones, and was the 18th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

12 of the 36 studies in Pre-Eclampsia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Pre-Eclampsia with a site in China, or all of them as a file.
02

Study summary

Preeclampsia (PE) is one of the leading causes of maternal and perinatal morbidity and mortality. This pregnancy-specific disorder poses to both pregnant women and their offspring an increased risk of immediate and long-term health problems. The study team is conducting a study entitled "FORECAST" (Implementation of First-trimester Screening and preventiOn of pREeClAmpSia Trial) and established the infrastructure for the first-trimester "screen and prevent" program for preterm PE. However, there is no established evidence regarding the benefit of scheduled labor induction versus expectant management among women identified as high-risk for PE with uncomplicated pregnancy at term. The investigators postulate that induction of labor at 39 weeks' gestation may possibly be an effective intervention to reduce placental complications in women with uncomplicated pregnancy by 39 weeks at high-risk PE women.

03

Conditions studied

  • Pre-Eclampsia
  • Induction of Labor

Keywords

  • aspirin
  • biomarker
  • blood pressure
  • hypertension
  • mean arterial pressure
  • placental growth factor
  • pre-eclampsia
  • prediction
  • uterine artery pulsatility index
  • induction of labor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age no less than 18 years
  • Singleton pregnancy with cephalic presentation and no to vaginal delivery
  • Live fetus
  • Screened high-risk for PE
  • Informed and written consent

Exclusion criteria

Exclusion Criteria:

  • Multiple pregnancy
  • Pregnant women who plan to have Cesarean delivery
  • Pregnancies complicated by the major fetal abnormality
  • Women who are severely ill, those with learning difficulties, or serious mental illness
  • Pregnant women with medical, obstetric, or fetal complications or any other indications for delivery before 39 weeks' gestation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
825 participants (estimated)

Study arms

  • Experimental
    IOL

    Preeclampsia High-risk Women schedule labor induction at 39 weeks of gestation

    Procedure: Induction of Labor

  • No intervention
    Expectant Management

    Preeclampsia High-risk Women under expectant management

Interventions

  • ProcedureInduction of Labor

    Induction of Labor at 39 weeks of gestation

06

What researchers measure

Primary outcomes

  1. the rate of adverse placental outcomes

    To compare the difference in the rate of adverse placental outcomes (PE, gestational hypertension (GH), SGA, stillbirth, perinatal death, placental abruption) in the induction of labor group with the expectant management group.

    Time frame: At Delivery

Secondary outcomes

  1. the rate of adverse maternal outcomes

    To compare the difference in the rate of maternal secondary outcomes including composite outcomes of the following: Cesarean delivery/indication for Cesarean delivery, operative vaginal delivery, indication for operative vaginal delivery, uterine incisional extensions during Cesarean delivery, chorioamnionitis, third-degree or fourth-degree perineal laceration, postpartum hemorrhage, postpartum infection, venous thromboembolism, number of hours in the labor and delivery unit, length of postpartum hospital stay, admission to the intensive care unit, and maternal death, between the induction of labor group and the expectant management group.

    Time frame: 6 weeks Postpartum

  2. the rate of adverse neonatal outcomes

    To compare the difference in the rate of neonatal secondary outcomes including the composite outcomes of the following: perinatal death or severe neonatal complications and consisted of one or more of the following during the antepartum or intrapartum period or during the delivery hospitalization between the induction of labor group and the expectant management group.

    Time frame: 28 days after birth

07

Study locations

5 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Aug 2024, 31 months after the start.

Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 31 months is above that.

Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Sep 24, 2021
StartActual
Jan 1, 2022
Primary completionEst.
Aug 30, 2024
CompletionEst.
Dec 31, 2024
Last update
May 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05056467
Collaborators
Hanoi Obstetrics and Gynecology Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Angel Women and Children Hospital, Rumah Sakit Anak dan Bunda Harapan Kita, National University Hospital, Singapore, Taiji Clinic, Taiwan, Siriraj Hospital
Responsible party
Chiu Yee Liona Poon (Professor (Clinical), Chinese University of Hong Kong) — Principal investigator
First posted
Sep 24, 2021
Start date
Jan 1, 2022
Primary completion
Aug 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 19, 2023

Study contacts

Liona POON, MD
Contact
liona.poon@cuhk.edu.hk
35051290

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion